Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice

BackgroundImmune checkpoint inhibitors (ICIs) are used widely for treating metastatic urothelial carcinoma (mUC). In practical settings, evidence is lacking on the efficacy of ICIs in some difficult-to-treat patients, such as those with end-stage renal disease (ESRD). Herein, we evaluate the safety...

Full description

Bibliographic Details
Main Authors: Ming-Chun Kuo, Po-Jung Su, Chun-Chieh Huang, Hao-Lun Luo, Tai-Jan Chiu, Shau-Hsuan Li, Chia-Che Wu, Ting-Ting Liu, Yuan-Tso Cheng, Chih-Hsiung Kang, Yu-Li Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor
end-stage renal disease
metastatic urothelial carcinoma
safety
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.584834/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.584834/full

Similar Items